Palatin Technologies and King Pharmaceuticals released new data from a Phase IIa trial that demonstrates the efficacy of its experimental drug bremelanotide for female sexual dysfunction. Almost three out of four women in the small study reported heightened genital arousal while taking the therapy, compared to one in four of the women receiving a placebo. Women receiving the therapy also engaged in a higher rate of sexual activity compared to the control group. Twenty-six women were involved in the mid-stage study. One hundred patients will be enrolled for Phase IIb.
- read the report from UPI on the trial data